Showing results (181-190 of 218) with videos related to
Sort By:
Pageof 22
Nature|May 11, 2022
Fundamental immune-oncogenicity trade-offs define driver mutation fitnessDavid Hoyos, Roberta Zappasodi, Isabell Schulze, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2015
Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung CancerScott N Gettinger, Leora Horn, Leena Gandhi, et al.Cancer Cell|January 12, 2024
Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancerDanish Memon, Adam J Schoenfeld, Darwin Ye, et al.Cancer Cell|April 17, 2018
Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung CancerMatthew D Hellmann, Tavi Nathanson, Hira Rizvi, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 6, 2021
Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation StatusBiagio Ricciuti, Kathryn C Arbour, Jessica J Lin, et al.Cancer Cell|March 31, 2023
Lineage tracing reveals clonal progenitors and long-term persistence of tumor-specific T cells during immune checkpoint blockadeJoy A Pai, Matthew D Hellmann, Jennifer L Sauter, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 9, 2018
Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)T R Cottrell, E D Thompson, P M Forde, et al.Cancer Discovery|November 17, 2019
Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell CancerLawrence Fong, Andrew Hotson, John D Powderly, et al.Cancer Research|February 3, 2016
STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor MicroenvironmentShohei Koyama, Esra A Akbay, Yvonne Y Li, et al.Cell|October 2, 2020
Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint InhibitionBarzin Y Nabet, Mohammad S Esfahani, Everett J Moding, et al.Pageof 22